Key result
Mavacamten reduces late gadolinium enhancement mass by ~2.0 g vs placebo in obstructive HCM.
Why the study?
Does mavacamten improve cardiac structure and function by CMR in Chinese adults with symptomatic obstructive hypertrophic cardiomyopathy?
RCT
Does mavacamten improve cardiac structure and function by CMR in Chinese adults with symptomatic obstructive hypertrophic cardiomyopathy?
In Chinese patients with obstructive HCM, mavacamten treatment for 30 weeks improved cardiac structure and function and reduced myocardial fibrosis as assessed by CMR.
Answers are grounded in this paper and cite their sources.
Supports mavacamten for remodeling in obstructive HCM; extends CMR data to Chinese adults.
BACKGROUND: Mavacamten, a first-in-class cardiac myosin inhibitor and the only approved cardiac myosin inhibitor worldwide, improved clinical symptoms and health status in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) in phase 3 EXPLORER-HCM (Clinical Study to Evaluate Mavacamten [MYK-461] in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy; NCT03470545) and EXPLORER-CN (A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM; NCT05174416). OBJECTIVES: The purpose of this work was to study the effect of mavacamten on cardiac structure and function by cardiac magnetic resonance (CMR) imaging in Chinese participants in EXPLORER-CN. METHODS: Eligible patients with obstructive HCM underwent CMR imaging at screening and week 30. Change from baseline to week 30 in left ventricular (LV) mass index was analyzed as a prespecified secondary outcome. Prespecified exploratory outcomes included changes in cellular hypertrophy, cardiac structure and function, and myocardial fibrosis by CMR. RESULTS: ]); all nominal P < 0.001. Reduction from baseline to week 30 in global mass of late gadolinium enhancement by 6 SDs was also observed with mavacamten vs placebo (mean between-group difference, -2.0 g [95% CI: -11.9 to 8.0 g]; nominal P = 0.007). CONCLUSIONS: At 30 weeks, improvements were observed in measures of cardiac structure and function, with reductions in indicators of myocardial fibrosis, in the mavacamten vs the placebo group. (A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM; NCT05174416).
No takes yet. Share an insight, caveat, or question.
Tian et al. (2025) conducted an RCT in symptomatic obstructive hypertrophic cardiomyopathy. Mavacamten vs. placebo was evaluated on Change from baseline to week 30 in global mass of late gadolinium enhancement by 6 SDs (MD -2.0 g, 95% CI -11.9 to 8.0, p=0.007). Mavacamten reduced global mass of late gadolinium enhancement compared to placebo at 30 weeks in Chinese patients with obstructive HCM.
Synapse has enriched 10 related papers. Consider them for comparative context: